Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Technology Officer | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,960 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 234 · Balance 81,960 F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on September 1, 2022. The number of shares withheld was determined based on the closing price of the issuer's common stock on September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on September 1, 2022. The number of shares withheld was determined based on the closing price of the issuer's common stock on September 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 21:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 234 | $9.32 | $2,180.88 |
DisclosureSEC source: 0002062007-26-000005 · primarydocument.xml · nonDerivative · entry 1 Malzahn Craig · CIK 0002062007 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,960 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on September 1, 2022. The number of shares withheld was determined based on the closing price of the issuer's common stock on September 1, 2026. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:43 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 35,402 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0002062007-26-000003 · primarydocument.xml · derivative · entry 2 Malzahn Craig · CIK 0002062007 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,402 Underlying: Common Stock · 35,402 shares Expires 2036-01-06 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:43 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 65,847 | $0.00 | $0.00 |
DisclosureSEC source: 0002062007-26-000003 · primarydocument.xml · nonDerivative · entry 1 Malzahn Craig · CIK 0002062007 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,194 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 1,238 | $14.40 | $17,827.20 |
DisclosureSEC source: 0002062007-26-000002 · primarydocument.xml · nonDerivative · entry 1 Malzahn Craig · CIK 0002062007 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,347 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 3, 2022, January 3, 2023, and January 2, 2024. The number of shares withheld was determined on January 2, 2026 based on the closing price of the issuer's common stock on December 31, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 16:49 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 234 | $8.93 | $2,089.62 |
DisclosureSEC source: 0001562180-25-006079 · primarydocument.xml · nonDerivative · entry 1 Malzahn Craig · CIK 0002062007 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,585 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on September 1, 2022. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 29, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.